6 Analysts Assess DaVita: What You Need To Know
Portfolio Pulse from Benzinga Insights
Six analysts have recently updated their ratings on DaVita (NYSE:DVA), showing a mix of opinions with 2 bullish and 4 indifferent. The average 12-month price target has been raised to $137.83 from $126.00, indicating a positive outlook on the stock. DaVita, a leading provider of dialysis services in the U.S., has shown strong financial performance with a notable revenue growth rate of 6.89% and impressive ROE and ROA figures. However, concerns are raised due to its high debt-to-equity ratio of 12.79.
May 06, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DaVita's stock may see a positive short-term impact due to the raised average price target and strong financial performance, despite mixed analyst ratings and concerns over high debt levels.
The increase in the average price target by analysts suggests a bullish sentiment towards DaVita's stock in the short term. The company's strong financial performance, including a notable revenue growth rate and high ROE and ROA, supports this positive outlook. However, the high debt-to-equity ratio is a concern that investors should monitor, as it could impact the company's financial flexibility and risk profile.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100